(Q33456315)

26 July 2017

1 reference

title

Anti-HPV vaccination: a review of recent economic data for Italy (English)

1 reference

26 July 2017

0 references

G Favato

3

0 references

Mauro Picardo

object named as

M Picardo

series ordinal

4

0 references

author name string

F S Mennini

series ordinal

1

1 reference

26 July 2017

S Costa

series ordinal

2

1 reference

26 July 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

26 July 2017

1 reference

26 July 2017

volume

27 Suppl 1

1 reference

26 July 2017

page(s)

A54-61

1 reference

Health and economic impact associated with a quadrivalent HPV vaccine in Italy

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.052

National Institute for Clinical Excellence and its value judgments

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.052

Does NICE have a cost-effectiveness threshold and what other factors influence its decisions? A binary choice analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.052

The potential cost-effectiveness of prophylactic human papillomavirus vaccines in Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.052

Cost-effectiveness analyses of human papillomavirus vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.052

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.052

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.052

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.052

Treatment patterns and associated costs for genital warts in Italy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.052

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.052

Economic evaluation of human papillomavirus vaccination in the United Kingdom

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.052

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.052

Value based pricing for NHS drugs: an opportunity not to be missed?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.052

An update on the first decade of the European centralized procedure: how many innovative drugs?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.052

On the decision rules of cost-effectiveness analysis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.052

Carrier screening for cystic fibrosis: costs and clinical outcomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.02.052

10.1016/J.VACCINE.2009.02.052

7 January 2021

Identifiers

DOI

1 reference

release_viqd4veixnc7zkd4lki36x4hd4

26 July 2017

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/viqd4veixnc7zkd4lki36x4hd4

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference